drugset
drugset / Trial / NCT01596400

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

NCT01596400 ↗

Phase 1 Completed 19 enrolled Kyowa Kirin Pharmaceutical Development Ltd
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.

Timeline

Start
2012-05
Primary completion
2015-08
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Granisetron Other / unclassified — Other

Indications

chemotherapy-induced toxicity